Safety and efficacy of a novel hepatobiliary MR contrast agent, Gd-DTPA-DeA

Results of phase I and phase II clinical trials

Akihiro Tanimoto, Masumi Kadoya, Yasutaka Kawamura, Ryohei Kuwatsuru, Takehiko Gokan, Shinji Hirohashi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: To assess the safety, effective dose, and efficacy of a novel hepatobiliary MR contrast agent Gd-DTPA-DeA for imaging liver tumors, from the clinical phase I and phase II trials in Japan. Materials and Methods: In a phase I trial, 33 healthy volunteers were intravenously administered a single dose of 0.03-10 μmol/kg of Gd-DTPA-DeA. In a nationwide phase II trial, 80 patients suspected to have hepatic mass were divided into three dosing groups: 2.5, 5.0, or 7.5 μmol/kg. T1-weighted gradient echo images were obtained before and after Gd-DTPA-DeA administration at three time points. Liver signal-to-noise ratio (SNR) and lesion-liver contrast-to-noise ratio (CNR) were calculated at each time point. A reading committee evaluated the contrast, diagnostic, and overall efficacy using a five-point scale. Results: In a phase I trial, dosages up to 10 μmol/kg were well tolerated by healthy volunteers. In a phase II trial, the contrast, diagnostic, and overall efficacy increased dose-dependently. The overall efficacy was 63.0%, 85.2%, and 88.0%, for 2.5, 5, and 7.5 μmol/kg, respectively. Liver SNR and CNR increase was greater at late phase than at early phase. No serious adverse events occurred. Conclusion: Gd-DTPA-DeA is a well-tolerated and promising contrast agent for liver MR imaging.

Original languageEnglish
Pages (from-to)499-508
Number of pages10
JournalJournal of Magnetic Resonance Imaging
Volume23
Issue number4
DOIs
Publication statusPublished - 2006 Apr

Fingerprint

Gadolinium DTPA
Phase II Clinical Trials
Contrast Media
Safety
Liver
Signal-To-Noise Ratio
Noise
Healthy Volunteers
Reading
Japan
Neoplasms

Keywords

  • Contrast media
  • Gadolinium
  • Gd-DTPA-DeA
  • Liver
  • Magnetic resonance imaging
  • Neoplasm

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Safety and efficacy of a novel hepatobiliary MR contrast agent, Gd-DTPA-DeA : Results of phase I and phase II clinical trials. / Tanimoto, Akihiro; Kadoya, Masumi; Kawamura, Yasutaka; Kuwatsuru, Ryohei; Gokan, Takehiko; Hirohashi, Shinji.

In: Journal of Magnetic Resonance Imaging, Vol. 23, No. 4, 04.2006, p. 499-508.

Research output: Contribution to journalArticle

Tanimoto, Akihiro ; Kadoya, Masumi ; Kawamura, Yasutaka ; Kuwatsuru, Ryohei ; Gokan, Takehiko ; Hirohashi, Shinji. / Safety and efficacy of a novel hepatobiliary MR contrast agent, Gd-DTPA-DeA : Results of phase I and phase II clinical trials. In: Journal of Magnetic Resonance Imaging. 2006 ; Vol. 23, No. 4. pp. 499-508.
@article{ad7e9f2dc76849119080b81f8e16790b,
title = "Safety and efficacy of a novel hepatobiliary MR contrast agent, Gd-DTPA-DeA: Results of phase I and phase II clinical trials",
abstract = "Purpose: To assess the safety, effective dose, and efficacy of a novel hepatobiliary MR contrast agent Gd-DTPA-DeA for imaging liver tumors, from the clinical phase I and phase II trials in Japan. Materials and Methods: In a phase I trial, 33 healthy volunteers were intravenously administered a single dose of 0.03-10 μmol/kg of Gd-DTPA-DeA. In a nationwide phase II trial, 80 patients suspected to have hepatic mass were divided into three dosing groups: 2.5, 5.0, or 7.5 μmol/kg. T1-weighted gradient echo images were obtained before and after Gd-DTPA-DeA administration at three time points. Liver signal-to-noise ratio (SNR) and lesion-liver contrast-to-noise ratio (CNR) were calculated at each time point. A reading committee evaluated the contrast, diagnostic, and overall efficacy using a five-point scale. Results: In a phase I trial, dosages up to 10 μmol/kg were well tolerated by healthy volunteers. In a phase II trial, the contrast, diagnostic, and overall efficacy increased dose-dependently. The overall efficacy was 63.0{\%}, 85.2{\%}, and 88.0{\%}, for 2.5, 5, and 7.5 μmol/kg, respectively. Liver SNR and CNR increase was greater at late phase than at early phase. No serious adverse events occurred. Conclusion: Gd-DTPA-DeA is a well-tolerated and promising contrast agent for liver MR imaging.",
keywords = "Contrast media, Gadolinium, Gd-DTPA-DeA, Liver, Magnetic resonance imaging, Neoplasm",
author = "Akihiro Tanimoto and Masumi Kadoya and Yasutaka Kawamura and Ryohei Kuwatsuru and Takehiko Gokan and Shinji Hirohashi",
year = "2006",
month = "4",
doi = "10.1002/jmri.20543",
language = "English",
volume = "23",
pages = "499--508",
journal = "Journal of Magnetic Resonance Imaging",
issn = "1053-1807",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Safety and efficacy of a novel hepatobiliary MR contrast agent, Gd-DTPA-DeA

T2 - Results of phase I and phase II clinical trials

AU - Tanimoto, Akihiro

AU - Kadoya, Masumi

AU - Kawamura, Yasutaka

AU - Kuwatsuru, Ryohei

AU - Gokan, Takehiko

AU - Hirohashi, Shinji

PY - 2006/4

Y1 - 2006/4

N2 - Purpose: To assess the safety, effective dose, and efficacy of a novel hepatobiliary MR contrast agent Gd-DTPA-DeA for imaging liver tumors, from the clinical phase I and phase II trials in Japan. Materials and Methods: In a phase I trial, 33 healthy volunteers were intravenously administered a single dose of 0.03-10 μmol/kg of Gd-DTPA-DeA. In a nationwide phase II trial, 80 patients suspected to have hepatic mass were divided into three dosing groups: 2.5, 5.0, or 7.5 μmol/kg. T1-weighted gradient echo images were obtained before and after Gd-DTPA-DeA administration at three time points. Liver signal-to-noise ratio (SNR) and lesion-liver contrast-to-noise ratio (CNR) were calculated at each time point. A reading committee evaluated the contrast, diagnostic, and overall efficacy using a five-point scale. Results: In a phase I trial, dosages up to 10 μmol/kg were well tolerated by healthy volunteers. In a phase II trial, the contrast, diagnostic, and overall efficacy increased dose-dependently. The overall efficacy was 63.0%, 85.2%, and 88.0%, for 2.5, 5, and 7.5 μmol/kg, respectively. Liver SNR and CNR increase was greater at late phase than at early phase. No serious adverse events occurred. Conclusion: Gd-DTPA-DeA is a well-tolerated and promising contrast agent for liver MR imaging.

AB - Purpose: To assess the safety, effective dose, and efficacy of a novel hepatobiliary MR contrast agent Gd-DTPA-DeA for imaging liver tumors, from the clinical phase I and phase II trials in Japan. Materials and Methods: In a phase I trial, 33 healthy volunteers were intravenously administered a single dose of 0.03-10 μmol/kg of Gd-DTPA-DeA. In a nationwide phase II trial, 80 patients suspected to have hepatic mass were divided into three dosing groups: 2.5, 5.0, or 7.5 μmol/kg. T1-weighted gradient echo images were obtained before and after Gd-DTPA-DeA administration at three time points. Liver signal-to-noise ratio (SNR) and lesion-liver contrast-to-noise ratio (CNR) were calculated at each time point. A reading committee evaluated the contrast, diagnostic, and overall efficacy using a five-point scale. Results: In a phase I trial, dosages up to 10 μmol/kg were well tolerated by healthy volunteers. In a phase II trial, the contrast, diagnostic, and overall efficacy increased dose-dependently. The overall efficacy was 63.0%, 85.2%, and 88.0%, for 2.5, 5, and 7.5 μmol/kg, respectively. Liver SNR and CNR increase was greater at late phase than at early phase. No serious adverse events occurred. Conclusion: Gd-DTPA-DeA is a well-tolerated and promising contrast agent for liver MR imaging.

KW - Contrast media

KW - Gadolinium

KW - Gd-DTPA-DeA

KW - Liver

KW - Magnetic resonance imaging

KW - Neoplasm

UR - http://www.scopus.com/inward/record.url?scp=33645664814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645664814&partnerID=8YFLogxK

U2 - 10.1002/jmri.20543

DO - 10.1002/jmri.20543

M3 - Article

VL - 23

SP - 499

EP - 508

JO - Journal of Magnetic Resonance Imaging

JF - Journal of Magnetic Resonance Imaging

SN - 1053-1807

IS - 4

ER -